Smith Zachary A, Moftakhar Parham, Malkasian Dennis, Xiong Zhenggang, Vinters Harry V, Lazareff Jorge A
Division of Neurosurgery, David Geffen School of Medicine at University of California Los Angeles, California 90095-7039, USA.
J Neurosurg. 2007 Sep;107(3 Suppl):255-62. doi: 10.3171/PED-07/09/255.
Diffuse villous hyperplasia of the choroid plexus is a rare but potential source of nonobstructive hydrocephalus. In addition to discussing the authors' staged surgical approach and medical management decisions in a patient with this rare and challenging condition, immunohistochemical studies of the choroid plexus epithelium are presented to examine the pathophysiological factors involved in abnormal cerebrospinal fluid (CSF) production in this disease. The patient, a 15-month-old girl born at 36 weeks' gestation, underwent a bilateral craniotomy with resection of the choroid plexus to treat her villous hyperplasia. Immunohistochemical studies of the resected choroid plexus were conducted for the purpose of examining the carbonic anhydrase II (CAII) enzyme and the aquaporin 1 (AQP1) membrane protein. Results were compared with immunohistochemical studies conducted in a small series of autopsy specimens of normal human choroid plexuses. There was no change in the immunoreactivity of CAII in the patient with villous hyperplasia compared with normal controls, whereas AQP1 immunoreactivity was significantly weaker in the patient compared with normal controls. Postoperatively, the patient's CSF overproduction resolved and her neurological symptoms improved over time. Shunting techniques and presently available pharmaceutical treatments alone do not provide adequate treatment of high-output CSF conditions. Surgical removal of the affected choroid plexus is a feasible and effective treatment. Results of the immunohistochemical studies reported here support the suggestion that the CAII enzyme is retained in villous hyperplasia of the choroid plexus. However, there appears to be decreased expression and perhaps downregulation of AQP1 in villous hyperplasia compared with normal choroid plexus. Future studies may elucidate the significance of these observations.
脉络丛弥漫性绒毛状增生是一种罕见但可能导致非梗阻性脑积水的病因。除了讨论作者针对患有这种罕见且具有挑战性病症的患者所采取的分期手术方法和药物治疗决策外,还展示了脉络丛上皮的免疫组织化学研究,以检查该疾病中异常脑脊液(CSF)产生所涉及的病理生理因素。该患者为一名孕36周出生的15个月大女孩,接受了双侧开颅手术并切除脉络丛以治疗其绒毛状增生。对切除的脉络丛进行免疫组织化学研究,目的是检测碳酸酐酶II(CAII)和水通道蛋白1(AQP1)膜蛋白。将结果与在一小系列正常人脉络丛尸检标本中进行的免疫组织化学研究进行比较。与正常对照相比,绒毛状增生患者的CAII免疫反应性没有变化,而该患者的AQP1免疫反应性明显弱于正常对照。术后,患者的脑脊液过度产生得到缓解,其神经症状随时间改善。单独的分流技术和目前可用的药物治疗不能充分治疗高输出脑脊液病症。手术切除受影响的脉络丛是一种可行且有效的治疗方法。此处报告的免疫组织化学研究结果支持以下观点:CAII酶在脉络丛绒毛状增生中得以保留。然而,与正常脉络丛相比,绒毛状增生中AQP1的表达似乎降低,甚至可能下调。未来的研究可能会阐明这些观察结果的意义。